DPP4 and cancer: Furthermore, the administration of the humanized anti-CD26 mAb YS110 yielded promising antineoplastic outcomes in advanced MPM that previously progressed on numerous chemotherapy agents, suggesting a more well-tolerated and possibly more effective treatment potential in certain cancers.